DUBLIN, Sept. 26, 2017 /PRNewswire/ -- Today, Allergan plc (NYSE: AGN) is pleased to announce that ACZONE ® (dapsone) Gel, 7.5%, a prescription medicine used on the skin (topical) to treat acne in ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), in partnership with SeegPharm SA (Lugano, Switzerland), is proud to announce the launch of Dapsone 5% Gel (NDC # ...

The FINANCIAL — Allergan plc on February 25 announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to market ACZONE (dapsone) Gel, 7.5%, a new prescription ...

Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes. Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes. The last ship date was March 31, 2016 and the ...

The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been ...

The FDA has approved a new gel to treat acne. Aczone Gel 5%, made by QLT Inc., is approved to treat acne vulgaris. That's a common skin condition in which oil and dead skin cells clog the skin's pores ...

Feb. 22, 2005 (New Orleans) -- A new topical gel containing 5% dapsone is showing promise in the treatment of acne vulgaris, according to results from two studies reported here at the 63rd annual ...

Acrux (ASX:ACR) jumped by as high as 27% this morning after announcing the US Food and Drug Administration's (FDA) approval of its generic version of Aczone Gel, 7.5% (Dapsone Gel, 7.5%). This ...

Launch continues the expansion of Cosette’s generic portfolio and global partnership strategy BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), in partnership with ...

Now approved by the US FDA, Acrux’s generic Dapsone Gel, 7.5% treats acne in patients 9 years and up. Acrux (ASX:ACR) jumped by as high as 27% this morning after announcing the US Food and Drug ...